Durvalumab hinders the evasion of the immune system by obstructing the interaction between programmed cell death ligand-1 (PD-L1) and programmed cell death protein-1 (PD-1), therefore enabling T-cells to identify and eliminate cancer cells [6]. Here, PDCD1 is linked to cancer.